SNSE - Sensei Biotherapeutics Inc Debt to Book Capitalization Ratio

Corporate company logo of senseibio.com (SNSE)

The dynamics of the debt-to-capitalization ratio on the balance sheet are based on Sensei Biotherapeutics revenues from grants and personalized oncology research. The development of targeted antibodies to block tumors and a plan to accelerate trials of drugs against solid tumors ensure increased stability. The value of 0.09 shows the current level of this metric, determining the risk of bankruptcy or the pace of business expansion.

SNSE Sensei Biotherapeutics Inc: Debt to Book Capitalization Ratio in the range 07/04/2022 - 06/16/2026
Finished products of Sensei Biotherapeutics Inc

Retaining leading immuno-oncologists through stock option programs minimizes the need for Sensei Biotherapeutics (SNSE) to secure costly loans. This indicator measures the share of total borrowings relative to equity, determining the degree of financial leverage. It is critical for investors to find a balance between default risk and the efficiency of using borrowed funds for growth. Analyzing the ratio of the company's financial debt to balance sheet equity allows for an assessment of the funding structure's stability. This chart confirms the issuer's solvency.

Competitors of Sensei Biotherapeutics

ImmunityBio, Inc. - Debts to Book Capitalization|immunocore.com - Debt to Book Value|JANX (Janux Therapeutics, Inc.) - Debt to Book Capitalization Ratio|RCUS: Debts to Book Value|Zymeworks Corp (ZYME) - Debt to Book Capitalization Ratio|TNGX (Tango Therapeutics Corp) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio IOVA (Iovance Biotherapeutics)|Debts to Book Value immatics.com|XNCR: Debts to Book Capitalization|Debt to Net Assets Compass Therapeutics Inc CMPX|REPL: Debt to Book Value|LYEL - Debts to Book Value|Debt to Book Value Innate Pharma S.A. (IPHA)|PYXS - Debt to Net Assets Ratio|cgen.com - Debts to Book Capitalization|IOBT (IO Biotech Inc) - Debts to Net Assets|Debt to Book Capitalization Ratio STRO|Debt to Book Value INKT|Debt to Book Capitalization Ratio HOWL (Werewolf Therapeutics)|Debt to Book Value immixbio.com IMMX|Debt to Book Value ALXO (ALX Oncology Holdings)|cuebiopharma.com - Debts to Book Capitalization|PDS Biotechnology Corp (PDSB) - Debt to Book Capitalization Ratio|SONN: Debt to Book Value Ratio|Debt to Book Capitalization Ratio MAIA|Debts to Book Value liminatuspharma.com|LAVA Therapeutics NV - Debt to Book Value|Debt to Net Assets NextCure Inc (NXTC)|Debt to Book Value Leap Therapeutics, Inc.|Debt to Book Capital intensitytherapeutics.com (INTS)|Debts to Book Capitalization Theriva Biologics, Inc.|Debt to Net Assets Ratio Gritstone bio Inc. GRTS|KA (Kineta) - Debts to Book Capitalization|NEXI: Debts to Book Value|Debt to Book Capitalization Ratio turnstonebio.com TSBX|Vaccinex Inc (VCNX) - Debt to Net Assets Ratio|HARP (Harpoon Therapeutics) - Debts to Book Capitalization